The project began in 2005. Fengrui worked closely with domestic vitamin B12 producers to successfully open up the market for a specific client in Japan, earning praise for their efforts. Over the past 20 years, Fengrui and its partner manufacturers have built strong relationships with nearly all generic drug companies in Japan that produce B12 series products. As a result, they have become the sole API supplier for most of these customers.

The project was initiated in 2010. In 2014, the supplier successfully passed the PMDA audit. Thanks to Fengrui's accurate understanding of market demand, even during the nitrosamine incident in 2018, the products provided by Fengrui and its partner manufacturers to customers remained compliant, with no reports of non-compliance or any returns. After years of continuous collaboration, Fengrui now supplies the majority of Japanese customers with significant consumption of sartan products and holds more than 50% of the entire Japanese generic drug market share.

This project began in 2015. In 2021, we helped the supplier successfully pass the PMDA audit, which officially validated its quality management system, production capacity, and the safety and effectiveness of its products. As a result, we gained the trust and support of numerous customers. Currently, Fengrui serves nearly all major generic drug customers in Japan, including several well-known pharmaceutical companies, and holds over 50% of the market share in the Japanese generic drug market. This achievement not only highlights our strengths in product quality and service but also reflects the high recognition of Fengrui within the market.

The project was initiated for research and development in early 2018 and successfully completed after one year. In 2019, it became the first time that the Japanese PMDA conducted an on-site inspection to assist the supplier, resulting in terminal customers capturing a 90% market share in Japan.